We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Authorized Generics and Biosimilars as Part of Drug Life Cycle Management.
- Abstract
Nowadays there is no longer a clear distinction between innovative pharmaceutical companies and generic and biosimilar manufacturers. The latter seek patent protection for new formulations or medical uses of known pharmaceuticals, and originators have responded by building their own generic divisions. Through them, innovative pharmaceutical companies are able to launch their own generics or biosimilars to cushion the loss of revenues after the expiry of blockbuster patents. In particular, in recent years so-called authorized generics and biosimilars have received increased attention as part of patent expiry strategies.
- Subjects
BIOSIMILARS; PHARMACEUTICAL industry; GENERIC drugs; MEDICAL patents; PATENT expiration
- Publication
GRUR International: Journal of European & International IP Law, 2020, Vol 69, Issue 11, p1105
- ISSN
2632-8550
- Publication type
Article
- DOI
10.1093/grurint/ikaa116